Australasian College of Dermatologists 2017 E-Posters

Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
Dr. Nicole Burkhardt
Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial
Dr. Nicole Burkhardt
Indirect comparison of ixekizumab (IXE) and secukinumab (SEC) using matched-adjusted indirect comparisons (MAIC)
Dr. Nicole Burkhardt
Ixekizumab (IXE) treatment enables rapid improvements in health-related quality of life (HRQoL) and itch: Results from UNCOVER-2 and UNCOVER-3
Dr. Nicole Burkhardt